Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2024-02-14 Earnings Release
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS." It provides a snapshot of the cash position (€4.9 M as of 31 December 2023) and updates on clinical trials and financing needs. This content is characteristic of an Earnings Release (ER), which typically announces key financial highlights for a period (in this case, year-end cash position) alongside operational updates. It is too brief and focused on highlights/announcement rather than being a comprehensive report (like 10-K or IR). It is not a transcript (CT), a management discussion (MDA), or a formal annual report (10-K). Therefore, ER is the most appropriate classification. FY 2023
2024-02-14 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2023 ET FAIT UN POINT SUR SES ACTIVITÉS
Earnings Release Classification · 1% confidence The document is a press release dated February 14th, titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 31 DÉCEMBRE 2023 ET FAIT UN POINT SUR SES ACTIVITÉS" (Theranexus publishes its cash position as of December 31, 2023, and provides an update on its activities). It reports the cash position (€4.9 M vs €6.0 M previously) and provides operational updates regarding clinical trials and future financing needs. It also announces the next financial publication date ("29 avril : Résultats financiers annuels 2023 & trésorerie T1-2024"). This content structure—a brief update on key financial metrics (cash) and operational milestones, often released outside of the main quarterly/annual filing cycle—is characteristic of an Earnings Release (ER) or a general operational update that precedes a full report. Since it focuses on the cash position and operational highlights rather than being a full, comprehensive report (like 10-K or IR), and it is not explicitly a transcript (CT) or a management discussion (MDA), the best fit is Earnings Release (ER), which covers initial financial results/highlights. It is not a Report Publication Announcement (RPA) because it contains substantive financial data and commentary, not just a notice that a report is available. FY 2023
2024-02-14 French
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023" and provides key financial figures (cash position at Q3 close, recent fundraising details, and expected tax credit receipt). This format, announcing specific financial metrics for a reporting period (Q3 2023), aligns best with an Earnings Release (ER), which typically provides the initial highlights of periodical financial results. It is too brief and focused on highlights to be a full Interim Report (IR) or Annual Report (10-K). It is not a transcript (CT), a management discussion (MDA), or a formal audit report (AR). 9M 2023
2023-10-17 English
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2023
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2023" (Theranexus Publishes its Cash Position as of September 30, 2023). It details the company's cash balance at the end of the third quarter (Q3), mentions a recent fundraising activity, and discusses the expected receipt of the Research Tax Credit (CIR). This content is a concise announcement of key financial metrics for a specific reporting period (Q3), which aligns perfectly with the definition of an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is too brief and focused on highlights to be a full Interim Report (IR). It is not a general regulatory filing (RNS) because it fits the specific 'ER' category. 9M 2023
2023-10-17 French
Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1
Earnings Release Classification · 1% confidence The document is a press release announcing highly promising interim results from a Phase I/II clinical trial for a drug candidate called Batten-1. It details efficacy and safety data (biomarker decline, clinical assessment) presented at a specific medical congress (NCL2023). This content structure—announcing key clinical trial data and quoting investigators/CEO—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on the results announcement rather than a full quarterly financial report (10-K or IR), and it is not a transcript (CT) or a formal presentation deck (IP), the most appropriate classification is Earnings Release (ER), as these often include clinical updates for biotech/pharma companies, or potentially Regulatory Filing (RNS) if it were a mandatory filing. Given the focus on presenting results and key figures, ER is a strong fit, although it is not strictly an 'earnings' report. However, it is a formal announcement of period-specific performance data (12-month interim results). It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available. I will classify it as ER based on the nature of the announcement (reporting period results). FY 2023
2023-09-29 English
Theranexus : Résultats très prometteurs à 12 mois dans l'étude de phase 1/2 de Batten-1
Earnings Release Classification · 1% confidence The document is a press release dated September 29, 2023, announcing 'très prometteurs' (very promising) interim efficacy and safety results after 12 months of treatment in the Phase 1/2 Batten-1 study, presented at the International Batten Disease Congress (NCL2023). It details clinical data (biomarker reduction, motor symptom progression) and includes quotes from the principal investigator and the CEO. This content—a detailed announcement of clinical trial results and their presentation at a conference—is characteristic of an Earnings Release (ER) or a specific clinical update. Since it focuses purely on the results announcement rather than a full periodic financial report (like 10-K or IR), and it is a formal press release format, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial/clinical results (key highlights). Although it discusses clinical data, the structure is that of a corporate announcement of results, not a formal regulatory filing like an IR or 10-K. It is not a transcript (CT) or a general regulatory filing (RNS). FY 2023
2023-09-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.